Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

This study is investigating whether using ablation (a targeted procedure to destroy tumors) on a small number of lung metastases, combined with ongoing systemic drug therapy, improves outcomes for patients with advanced liver cancer (hepatocellular carcinoma) that has spread to the lungs. **You may be eligible if...** - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) - You have a small number of lung metastases (up to 5 sites, each no larger than 5 cm) - You have been receiving systemic therapy for at least 3 months and your liver tumors are stable or responding - You are between 18 and 75 years old and in reasonably good physical health - Your liver function is within acceptable limits (Child-Pugh class A or B) **You may NOT be eligible if...** - You have more than 5 metastatic sites - Your cancer has not responded to lenvatinib - Your lung metastases are larger than 5 cm - You have less than 3 months life expectancy - You have had another type of cancer Talk to your doctor to see if this trial is right for you.